A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China

Conclusion This analysis suggests that treatment with clopidogrel plus ASA for up to 1 year for patients with NSTEACS is cost effective in the local context of China from a public payers’ perspective. Funding Sanofi China.

http://link.springer.com/10.1007/s12325-016-0375-9

Source: Advances in Therapy - July 10, 2016 Category: Drugs & Pharmacology Source Type: research